SCHEMBL18264161

SCHEMBL18264161

Nc1n[nH]c2c1c(Nc1ccc(F)cc1)nc1ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.51
LMNA P02545 4/20 0.45
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 2/20 0.45
HPGD P15428 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
CYP1A2 P05177 3/20 0.44
HSD17B10 Q99714 3/20 0.44
MAPT P10636 3/20 0.44
CYP3A4 P08684 2/20 0.44
USP2 O75604 2/20 0.44
CYP2C19 P33261 2/20 0.44
CLK4 Q9HAZ1 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
KDM1A O60341 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18264175 0.91 KDM1A (0.52) ABCG2LMNAALDH1A1KDM4EHPGD
SCHEMBL18264402 0.91 EGFR (0.47) ABCG2NPC1RAB9AMEN1KMT2A
SCHEMBL18264159 0.88 MAPT (0.52) ABCG2LMNAALDH1A1KDM4EHPGD
SCHEMBL18264174 0.88 GAA (0.52) ABCG2LMNAALDH1A1MEN1KMT2A
SCHEMBL18264156 0.88 NPY5R (0.50) ABCG2LMNAALDH1A1KDM4ENPC1
SCHEMBL18264164 0.87 ABCG2 (0.52) ABCG2RAB9AMEN1KMT2ATDP1
SCHEMBL18264154 0.84 ABCG2 (0.53) ABCG2NPC1RAB9AMEN1KMT2A
SCHEMBL18264139 0.84 KDM1A (0.52) ABCG2NPC1RAB9ACLK4TSHR
SCHEMBL18264134 0.84 NPY5R (0.53) ABCG2LMNAALDH1A1KDM4ENPC1
SCHEMBL18264176 0.82 MAPT (0.49) ABCG2ALDH1A1KDM4EHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3302060-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2020-02-12 EP claimed
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE KAOHSIUNG MEDICAL UNIVERSITY (TW) 2018-08-02 US claimed
EP-3302060-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE Kaohsiung Medical University (TW) 2018-04-11 EP claimed
WO-2016191576-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE DCB-USA LLC (US) 2016-12-01 WO claimed
EP-3662751-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2021-10-13 EP disclosed
EP-3662751-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2021-10-13 EP disclosed
US-11135206-B2 Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-10-05 US disclosed
US-11135206-B2 Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-10-05 US disclosed
US-11052072-B2 Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-07-06 US disclosed
US-11052072-B2 Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-07-06 US disclosed
EP-3662751-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE Kaohsiung Medical University (TW) 2020-06-10 EP disclosed
EP-3662751-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE Kaohsiung Medical University (TW) 2020-06-10 EP disclosed
EP-3302060-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2020-02-12 EP disclosed
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE KAOHSIUNG MEDICAL UNIVERSITY (TW) 2018-08-02 US disclosed
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE KAOHSIUNG MEDICAL UNIVERSITY (TW) 2018-08-02 US disclosed
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE KAOHSIUNG MEDICAL UNIVERSITY (TW) 2018-08-02 US disclosed
EP-3302060-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE Kaohsiung Medical University (TW) 2018-04-11 EP disclosed
CN-107708419-A Pyrazolo [4,3-c ] quinoline derivatives having inhibitory activity on bacterial glucuronidase 高雄医学大学 2018-02-16 CN disclosed
WO-2016191576-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE DCB-USA LLC (US) 2016-12-01 WO disclosed
WO-2016191576-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE DCB-USA LLC (US) 2016-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE UGT1A3, UGT1A1, GUSB ABCG2 1289/4885LMNA 3635/4885ALDH1A1 43/4885
US-11052072-B2 Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase UGT1A3, UGT1A1, DPP3 ABCG2 1243/4885LMNA 3659/4885ALDH1A1 42/4885
US-11135206-B2 Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase UGT1A3, UGT1A1, DPP3 ABCG2 1243/4885LMNA 3659/4885ALDH1A1 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.